Kazia Therapeutics Files Prospectus Supplement
Ticker: KZIA · Form: 424B3 · Filed: Apr 15, 2026
Sentiment: neutral
Topics: prospectus-supplement, offering, pharmaceuticals
TL;DR
Kazia Therapeutics is selling more stock, filing a prospectus supplement on 4/15/26.
AI Summary
Kazia Therapeutics Ltd. filed a prospectus supplement on April 15, 2026, related to its common stock. The filing details the terms of a public offering, though specific dollar amounts and the number of shares offered are not immediately clear from this summary document.
Why It Matters
This filing indicates Kazia Therapeutics is actively seeking to raise capital through a public offering, which could fund its ongoing research and development efforts.
Risk Assessment
Risk Level: medium — Prospectus supplements often precede or accompany stock offerings, which can dilute existing shareholders and are subject to market volatility.
Key Numbers
- 424B3 — Form Type (Indicates a prospectus supplement filing)
- 333-292303 — File Number (Associated with the registration statement for the offering)
Key Players & Entities
- Kazia Therapeutics Ltd. (company) — Filer of the prospectus supplement
- 0001075880 (company) — CIK number for Kazia Therapeutics Ltd.
- 2026-04-15 (date) — Filing date of the prospectus supplement
FAQ
What is the purpose of this 424B3 filing?
This filing is a prospectus supplement for Kazia Therapeutics Ltd., providing additional details about a public offering of its common stock.
When was this prospectus supplement filed?
The prospectus supplement was filed on April 15, 2026.
What is the CIK number for Kazia Therapeutics Ltd.?
The CIK number for Kazia Therapeutics Ltd. is 0001075880.
What is the business address of Kazia Therapeutics Ltd.?
The business address is THREE INTERNATIONAL TOWERS, LEVEL 24, 300 BARANGAROO AVENUE, SYDNEY NSW, Australia 2000.
What SIC code is associated with Kazia Therapeutics Ltd.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 424B3 (Form 424B3) was filed with the SEC on April 15, 2026 regarding KAZIA THERAPEUTICS LTD (KZIA).